Advanced molecular immunology and cell biology (AM_470656)
Class notes
Lecture 6. Immune deficiencies (AM_470656)
4 views 0 purchase
Course
Advanced molecular immunology and cell biology (AM_470656)
Institution
Vrije Universiteit Amsterdam (VU)
Book
The Immune System
Information on etiology, and how to identify and classify them. Severe combined immunodeficiencies (SCID), atypical leaky SCID, combined immunodeficiencies diagnosis and treatment of SCID. Antibody immunodeficiencies.
Lecture 9. The immune system in the brain (neuro-immunology) (AM_470656)
Lecture 7. Immune response to glycolipids and polysaccharides (AM_470656)
Lecture 5. Immunometabolism and the immune system (AM_470656)
All for this textbook (10)
Written for
Vrije Universiteit Amsterdam (VU)
Biomedical Sciences
Advanced molecular immunology and cell biology (AM_470656)
All documents for this subject (24)
Seller
Follow
nuriafarras
Content preview
Molecular Cell Biology and Immunology
Lecture 6. Primary immunodeficiencies: inborn errors of immunity
INDEX
1. Immunodeficiencies – Introduction ............................................................................................................................................................. 1
1.1. Primary immunodeficiencies .............................................................................................................................................................. 1
2. Genetic aetiology of PID ............................................................................................................................................................................. 1
2.1. Consanguineous families .................................................................................................................................................................... 1
2.2. Variable presentation of monogenic PIDs ........................................................................................................................................... 2
2.3. Non-monogenic diseases and unknown aetiologies ............................................................................................................................ 2
2.4. Known PIDs ........................................................................................................................................................................................ 2
3. How do we find the genetic mutations in the PID patients? ........................................................................................................................ 2
3.1. Why look for causative mutations in PID patients? ............................................................................................................................. 2
3.2. Finding genetic mutations in PID patients ........................................................................................................................................... 2
3.2.1. Next generation sequencing ................................................................................................................................................................ 3
3.2.2. Identifying mutations ........................................................................................................................................................................... 3
3.2.3. Mutations found in the RIPK1 gene ..................................................................................................................................................... 3
4. PID classification ........................................................................................................................................................................................ 3
4.1. Antibody deficiencies ......................................................................................................................................................................... 4
4.2. Diseases caused by intrinsic T cell defect ............................................................................................................................................ 4
5. Severe combined immunodeficiencies (SCID) .............................................................................................................................................. 4
5.1. Immunological mechanisms of SCID.................................................................................................................................................... 4
5.2. SCID-X1 ............................................................................................................................................................................................... 4
5.2.1. David Vetter, the Bubble boy ............................................................................................................................................................... 5
5.3. SCID patient numbers ......................................................................................................................................................................... 5
6. Atypical leaky SCIDs.................................................................................................................................................................................... 5
6.1. Omen syndrome ................................................................................................................................................................................. 5
7. Combined immunodeficiencies (CIDs) ......................................................................................................................................................... 5
7.1. Diagnostics of combined immunodeficiencies ..................................................................................................................................... 5
8. Treatment of SCID ...................................................................................................................................................................................... 6
8.1. Hematopoietic stem-cell transplantation (HSCT)................................................................................................................................. 6
8.2. Gene therapy ...................................................................................................................................................................................... 6
9. Predominantly antibody deficiencies .......................................................................................................................................................... 7
9.1. Group 1. antibody deficiencies ........................................................................................................................................................... 7
9.2. Group 3. Hyper IgM – class switch recombination defect .................................................................................................................... 8
9.3. Diagnostic of antibody deficiencies ..................................................................................................................................................... 8
9.4. Treatment .......................................................................................................................................................................................... 8
, Patterns in case study: they all had mutations in the RIPK1 gene, a primary immunodeficiency.
1. IMMUNODEFICIENCIES – INTRODUCTION
They are disorders of the immune system that manifest with increased susceptibility to infection. we are all susceptible to infection but our IS
gets us through it, in the case of immunodeficiencies there is an impairment of the IS and they suffer recurrent or more severe infections by
common or unusual pathogens. In addition, immunodeficiencies might be associated with autoinflammatory or autoimmune manifestations.
We can distinguish two types of immunodeficiencies:
- Primary (PIDs): they are inborne errors caused by genetic mutations.
- Secondary (SIDs): caused by secondary factors (HIV, chemotherapy, leukemia, diabetes, etc.).
1.1. PRIMARY IMMUNODEFICIENCIES
PIDs are an extremely heterogeneous group of diseases, there are more than 450 types identified and the numbers increase. A classification in
published every 2 years, where new diseases are included.
Most PIDs are rare diseases, there are hundreds of patients known in the population and in some of them, only a few patients have been
reported. They are rare but there has to be reported, as new patients can be identified later. They also help learn about the IS.
The prevalence varies in different countries: in UK is 5.9/100,000, in Turkey 30.5/100,000, etc. They are underestimated, specially in countries
where the diagnostics is difficult.
Raising awareness about PIDs in clinicians, patients and families is important to identify the
patients and get a correct treatment. → Jeffrey Modell foundation is a foundation generated
by a family that had a son with PID. They have contributed a lot in raising awareness. Together
with clinicians they came up with a list of 10 warning signs of these PIDs: 4 or more infections
within one year, etc.
If there are 2 or more signs, the parents have to speak to the physician about a possible PID.
It gives an idea of how a PID can manifest early in life.
PIDs are inborn errors of the IS, this makes it that
many of them are diagnosed in children.
Surprisingly, 50% of PIDs are diagnosed in adults.
There are some warning signs per adults also.
Early PID diagnostics is critical, this leads to:
- Better and more adequate treatment.
- Increases prognosis and reduces mortality.
- Reduces the cost of treatment. Treating undiagnosed PID patients are much higher than the cost of treating a diagnosed PID.
There are environmental factors that impact the manifestation of the PID in some patients.
2. GENETIC AETIOLOGY OF PID
Most of them are caused by monogenic diseases, they are caused by rare mutations that have a big impact on the immune system. A single
mutation is enough to cause the disease, they can be recessive, dominant, or X-chromosome-linked genes. The ones carried in the X gene are
more predominantly seen in boys and girls will be carriers.
The recessive mutations are seen in families where the parents are related with each other.
2.1. CONSANGUINEOUS FAMILIES
There was a paper in nature communications of people that were probable of being affected in consanguineous families. They can be present
in the old or new times. Nowadays whole genome data has allowed to find the frequency of this mutations in the population: 1 in 360,000
people.
1
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller nuriafarras. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $3.85. You're not tied to anything after your purchase.
